Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571446311> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2571446311 endingPage "S1243" @default.
- W2571446311 startingPage "S1242" @default.
- W2571446311 abstract "There is no optimal therapy established for those who have progressed with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). And some preclinical study indicated that the addition of S-1 to EGFR-TKIs might overcome EGFR-TKI resistance. This study was conducted to investigate the efficacy and safety of the combination therapy of S-1 and EGFR-TKIs for patients failed the previous EGFR-TKI treatments. All patients who received the combination therapy of S-1 and EGFR-TKIs beyond progressive disease with EGFR-TKI monotherapy in the Cancer Hospital, the Chinese Academy of Medical Sciences between 2013 and 2016 with complete records were enrolled in this study. The primary endpoint was progression-free survival (PFS), while the disease control rate and safety were secondary endpoints. Multivariate analysis for survival was conducted including age, gender, initiation of EGFR-TKI, the choice of EGFR-TKI, the best efficacy while using EGFR monotherapy and the choice of S-1 and EGFR-TKI. A total of 43 non-small-lung cancer (NSCLC) patients who met the inclusion criteria were enrolled in this study. The median PFS for all patients was 5.47 months (95% confidence interval [CI] 3.444-7.489). The disease control rate is 67.4% (29/43). There was no grade 4 toxicity and no grade 3 hematologic toxicity in this study. One patient has grade 3 elevated total serum bilirubin. Cox analysis showed that the combination treatment of S-1 and erlotinib was associated with decreased PFS comparing the gefitinib (hazards ratio [HR] 8.401, 95% CI 2.781-25.379, p<0.001). Besides, male (HR 0.389, 95% CI 0.162-0.934, p=0.035) and patients with SD (HR 0.303, 95% CI 0.124-0.471, p=0.009) or PD (HR 0.031, 95% CI 0.002-0.450, p=0.011) in the monotherapy of EGFR-TKIs were associated with increased PFS. The combination treatment of S-1 and EGFR-TKIs is effective and well-tolerated treatment for those failed prior EGFR-TKI. This strategy is promising to overcome EGFR-TKI resistance in NSCLC. A prospective study will be needed to confirm our studys." @default.
- W2571446311 created "2017-01-13" @default.
- W2571446311 creator A5003642180 @default.
- W2571446311 creator A5009514805 @default.
- W2571446311 creator A5017252801 @default.
- W2571446311 creator A5045176687 @default.
- W2571446311 creator A5065246588 @default.
- W2571446311 creator A5068920157 @default.
- W2571446311 creator A5070806123 @default.
- W2571446311 date "2017-01-01" @default.
- W2571446311 modified "2023-10-17" @default.
- W2571446311 title "P3.02b-085 The Combination Therapy of S-1 and the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors beyond Progressive Disease" @default.
- W2571446311 doi "https://doi.org/10.1016/j.jtho.2016.11.1752" @default.
- W2571446311 hasPublicationYear "2017" @default.
- W2571446311 type Work @default.
- W2571446311 sameAs 2571446311 @default.
- W2571446311 citedByCount "1" @default.
- W2571446311 countsByYear W25714463112017 @default.
- W2571446311 crossrefType "journal-article" @default.
- W2571446311 hasAuthorship W2571446311A5003642180 @default.
- W2571446311 hasAuthorship W2571446311A5009514805 @default.
- W2571446311 hasAuthorship W2571446311A5017252801 @default.
- W2571446311 hasAuthorship W2571446311A5045176687 @default.
- W2571446311 hasAuthorship W2571446311A5065246588 @default.
- W2571446311 hasAuthorship W2571446311A5068920157 @default.
- W2571446311 hasAuthorship W2571446311A5070806123 @default.
- W2571446311 hasBestOaLocation W25714463111 @default.
- W2571446311 hasConcept C121608353 @default.
- W2571446311 hasConcept C126322002 @default.
- W2571446311 hasConcept C143998085 @default.
- W2571446311 hasConcept C168563851 @default.
- W2571446311 hasConcept C203092338 @default.
- W2571446311 hasConcept C207103383 @default.
- W2571446311 hasConcept C2776256026 @default.
- W2571446311 hasConcept C2776999253 @default.
- W2571446311 hasConcept C2778087573 @default.
- W2571446311 hasConcept C2778822529 @default.
- W2571446311 hasConcept C2779134260 @default.
- W2571446311 hasConcept C2779438470 @default.
- W2571446311 hasConcept C2780580887 @default.
- W2571446311 hasConcept C2909325608 @default.
- W2571446311 hasConcept C44249647 @default.
- W2571446311 hasConcept C71924100 @default.
- W2571446311 hasConceptScore W2571446311C121608353 @default.
- W2571446311 hasConceptScore W2571446311C126322002 @default.
- W2571446311 hasConceptScore W2571446311C143998085 @default.
- W2571446311 hasConceptScore W2571446311C168563851 @default.
- W2571446311 hasConceptScore W2571446311C203092338 @default.
- W2571446311 hasConceptScore W2571446311C207103383 @default.
- W2571446311 hasConceptScore W2571446311C2776256026 @default.
- W2571446311 hasConceptScore W2571446311C2776999253 @default.
- W2571446311 hasConceptScore W2571446311C2778087573 @default.
- W2571446311 hasConceptScore W2571446311C2778822529 @default.
- W2571446311 hasConceptScore W2571446311C2779134260 @default.
- W2571446311 hasConceptScore W2571446311C2779438470 @default.
- W2571446311 hasConceptScore W2571446311C2780580887 @default.
- W2571446311 hasConceptScore W2571446311C2909325608 @default.
- W2571446311 hasConceptScore W2571446311C44249647 @default.
- W2571446311 hasConceptScore W2571446311C71924100 @default.
- W2571446311 hasIssue "1" @default.
- W2571446311 hasLocation W25714463111 @default.
- W2571446311 hasOpenAccess W2571446311 @default.
- W2571446311 hasPrimaryLocation W25714463111 @default.
- W2571446311 hasRelatedWork W1971737397 @default.
- W2571446311 hasRelatedWork W2017389411 @default.
- W2571446311 hasRelatedWork W2060263774 @default.
- W2571446311 hasRelatedWork W2115065459 @default.
- W2571446311 hasRelatedWork W2186047679 @default.
- W2571446311 hasRelatedWork W2297986000 @default.
- W2571446311 hasRelatedWork W2319187913 @default.
- W2571446311 hasRelatedWork W2416274847 @default.
- W2571446311 hasRelatedWork W2610370832 @default.
- W2571446311 hasRelatedWork W2978946191 @default.
- W2571446311 hasVolume "12" @default.
- W2571446311 isParatext "false" @default.
- W2571446311 isRetracted "false" @default.
- W2571446311 magId "2571446311" @default.
- W2571446311 workType "article" @default.